Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

US biotech ImmunityBio (Nasdaq: IBRX) has secured $75 million through a direct offering with a single institutional investor, ...

The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson (NYSE: JNJ), for some adult patients in England.

California-based clinical-stage biotech Tempest Therapeutics (Nasdaq: TPST) has announced that the company plans to explore a ...

At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics (Nasdaq: AXSM) presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation ...

Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s ...

The first comprehensive analysis of clinical trials in the UK has found the country remains a global leader in medical ...

Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein ...

US health technology assessor the Institute for Clinical and Economic Review (CER), in collaboration with researchers from ...

South Korea’s Samsung Bioepis presented data, including the budget impact analysis on ustekinumab biosimilars’ cost savings ...

The All-Russian Union of Patients (VSP) has called on Russia’s Deputy Prime Minister, Tatyana Golikova, to expand the list of ...